|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atenolol#Use in Specific Populations]] |
| {{Atenolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy and Fetal Injury===
| |
| | |
| Atenolol can cause fetal harm when administered to a pregnant woman. Atenolol crosses the placental barrier and appears in cord blood. Administration of atenolol, starting in the second trimester of pregnancy, has been associated with the birth of infants that are small for gestational age. No studies have been performed on the use of atenolol in the first trimester and the possibility of fetal injury cannot be excluded. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
| |
| | |
| Neonates born to mothers who are receiving TENORMIN at parturition or breast-feeding may be at risk for [[hypoglycemia]] and [[bradycardia]]. Caution should be exercised when TENORMIN is administered during pregnancy or to a woman who is breast-feeding. (See PRECAUTIONS, Nursing Mothers.)
| |
| | |
| Atenolol has been shown to produce a dose-related increase in embryo/fetal resorptions in rats at doses equal to or greater than 50 mg/kg/day or 25 or more times the maximum recommended human antihypertensive dose1. Although similar effects were not seen in rabbits, the compound was not evaluated in rabbits at doses above 25 mg/kg/day or 12.5 times the maximum recommended human antihypertensive dose1. | |
| | |
| ===Nursing Mothers===
| |
| | |
| Atenolol is excreted in human breast milk at a ratio of 1.5 to 6.8 when compared to the concentration in plasma. Caution should be exercised when TENORMIN is administered to a nursing woman. Clinically significant [[bradycardia]] has been reported in breast-fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects.
| |
| | |
| Neonates born to mothers who are receiving TENORMIN at parturition or breast-feeding may be at risk for [[hypoglycemia]] and [[bradycardia]]. Caution should be exercised when TENORMIN is administered during pregnancy or to a woman who is breast-feeding (See WARNINGS, Pregnancy and Fetal Injury).
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| ====Hypertension and Angina Pectoris Due to Coronary Atherosclerosis====
| |
| | |
| Clinical studies of TENORMIN did not include sufficient number of patients aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
| |
| | |
| ====Acute Myocardial Infarction====
| |
| | |
| Of the 8,037 patients with suspected acute [[myocardial infarction]] randomized to TENORMIN in the ISIS-1 trial (See CLINICAL PHARMACOLOGY), 33% (2,644) were 65 years of age and older. It was not possible to identify significant differences in efficacy and safety between older and younger patients; however, elderly patients with systolic blood pressure < 120 mmHg seemed less likely to benefit (See INDICATIONS AND USAGE).
| |
| | |
| In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Evaluation of patients with hypertension or myocardial infarction should always include assessment of renal function.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TENORMIN (ATENOLOL) TABLET [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcfc9676-4edc-460e-6199-8161b824908f | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
|
| |
|
| [[Category:Beta blockers]] | | [[Category:Beta blockers]] |
| Line 43: |
Line 5: |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |